Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Katherine M. Hammitt"'
Autor:
Marlies Wijsenbeek, Maria Molina-Molina, Olivier Chassany, John Fox, Liam Galvin, Klaus Geissler, Katherine M. Hammitt, Michael Kreuter, Teng Moua, Emily C. O'Brien, Ashley F. Slagle, Anna Krasnow, Matthew Reaney, Michael Baldwin, Natalia Male, Klaus B. Rohr, Jeff Swigris, Katerina Antoniou
Publikováno v:
ERJ Open Research, Vol 8, Iss 2 (2022)
Background An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials. Methods
Externí odkaz:
https://doaj.org/article/2b4d0656e26e4705841c755f6e5ab14a
Publikováno v:
Tuesday, April 25.
Autor:
Barbara Caffery, Rebecca Petris, Katherine M Hammitt, Michela Montecchi-Palmer, Sameena Haque, Jean-Pierre Malkowski, Stefano Barabino
Publikováno v:
European journal of ophthalmology.
Purpose To understand patients’ perspectives on living with dry eye disease (DED), and on the unmet needs in DED and chronic ocular surface pain (COSP) management. Methods A moderated, structured discussion with patients with ocular surface disease
Autor:
Kieron Dunleavy, Katherine M. Hammitt
Five percent to 10% of Sjögren’s patients develop a malignancy, most commonly a non-Hodgkin’s lymphoma. This prevalence is the highest among any autoimmune disorder. The most frequent cancer in Sjögren’s is B-cell lymphoma of the mucosa-assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34a51ac2c03eee0c61c0d3d8568ba002
https://doi.org/10.1093/oso/9780197502112.003.0037
https://doi.org/10.1093/oso/9780197502112.003.0037
After many years with little forward movement in Sjögren’s, promising approaches to disease management are on the horizon, including biomarker discoveries, new metrics to assess disease activity, and advanced imaging technologies. Some of the area
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca1816876aaa198fb7e6e8d1192a3607
https://doi.org/10.1093/oso/9780197502112.003.0048
https://doi.org/10.1093/oso/9780197502112.003.0048
Autor:
Thomas D. Sutton, Katherine M. Hammitt
Sjögren’s can result in a high financial cost to patients and their families. Due to the effects of this potentially disabling disease, some Sjögren’s patients are unable to work and face the loss of their income. At the same time, these patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::648bdb4c050184f8d004bd4f2cd7e201
https://doi.org/10.1093/oso/9780197502112.003.0047
https://doi.org/10.1093/oso/9780197502112.003.0047
Autor:
Katherine M. Hammitt
As the Sjögren’s Foundation and others bring researchers, clinicians, patients, government, and industry together, advances in Sjögren’s and the resulting benefits will occur at a pace never before seen in history. Collaboration, coupled with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91e54ac14bcf11f77c7763ee0758f0c7
https://doi.org/10.1093/oso/9780197502112.003.0051
https://doi.org/10.1093/oso/9780197502112.003.0051
Autor:
Emily C. O'Brien, Olivier Chassany, Teng Moua, Klaus B Rohr, Anna Krasnow, Matthew Reaney, Ashley Slagle, Michael Baldwin, Marlies S. Wijsenbeek, Klaus Geissler, Jeffrey J. Swigris, Katherine M. Hammitt, Katerina M. Antoniou, Liam Galvin, John Fox, Maria del Carmen Bisi Molina, Michael Kreuter, Natalia Male
Publikováno v:
Chest. 160:A1267-A1269
Autor:
Alan N. Baer, Katherine M. Hammitt
Publikováno v:
Arthritis & Rheumatology. 74:367-368
We thank Dr. Cottin for supporting our call to adopt the term 'disease' in lieu of 'syndrome' when referring to the distinct systemic disease described by Henrik Sjogren in a comprehensive 150-page monograph published in 1933.
Autor:
Katherine M. Hammitt, Alan N. Baer
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.). 73(7)
Sjogren's syndrome should henceforth be known as Sjogren's disease. Our call for this is based on the precedence for such name changes in rheumatology as well as important differences between syndrome and disease. In addition, the struggle faced by S